phentermine has been researched along with Diseases, Metabolic in 2 studies
Phentermine: A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Controlled-release phentermine/topiramate (PHEN/TPM CR), as an adjunct to lifestyle modification, has previously shown significant weight loss compared with placebo in a 56-wk study in overweight and obese subjects with ≥2 weight-related comorbidities." | 9.16 | Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. ( Allison, DB; Bowden, CH; Day, WW; Gadde, KM; Garvey, WT; Look, M; Peterson, CA; Ryan, DH; Schwiers, M, 2012) |
| " Controlled-release phentermine/topiramate (PHEN/TPM CR), as an adjunct to lifestyle modification, has previously shown significant weight loss compared with placebo in a 56-wk study in overweight and obese subjects with ≥2 weight-related comorbidities." | 5.16 | Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. ( Allison, DB; Bowden, CH; Day, WW; Gadde, KM; Garvey, WT; Look, M; Peterson, CA; Ryan, DH; Schwiers, M, 2012) |
| " Phentermine is a noradrenergic sympathomimetic amine approved for short-term treatment of obesity." | 4.86 | Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease. ( Bays, H, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bays, H | 1 |
| Garvey, WT | 1 |
| Ryan, DH | 1 |
| Look, M | 1 |
| Gadde, KM | 1 |
| Allison, DB | 1 |
| Peterson, CA | 1 |
| Schwiers, M | 1 |
| Day, WW | 1 |
| Bowden, CH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 3, Double-Blind, Placebo-Controlled, Multicenter Extension Study (From Study OB-303 [NCT00553787]) to Determine the Safety and Efficacy Of VI-0521 for the Long-Term Treatment Of Obesity in Adults With Obesity-Related Co-Morbid Conditions.[NCT00796367] | Phase 3 | 676 participants (Actual) | Interventional | 2008-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00796367)
Timeframe: From baseline to end of treatment
| Intervention | percent weight loss (Least Squares Mean) |
|---|---|
| Placebo | -1.8 |
| VI-0521 Mid | -9.32 |
| VI-0521 Top | -10.5 |
(NCT00796367)
Timeframe: Baseline to End of Treatment
| Intervention | percent participants (Number) |
|---|---|
| Placebo | 30 |
| VI-0521 Mid | 75.2 |
| VI-0521 Top | 79.3 |
1 review available for phentermine and Diseases, Metabolic
| Article | Year |
|---|---|
Phentermine, topiramate and their combination for the treatment of adiposopathy ('sick fat') and metabolic disease.
Topics: Adipose Tissue; Adiposity; Animals; Anti-Obesity Agents; Appetite Depressants; Appetite Regulation; | 2010 |
1 trial available for phentermine and Diseases, Metabolic
| Article | Year |
|---|---|
Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study.
Topics: Adult; Anti-Obesity Agents; Cardiovascular Diseases; Delayed-Action Preparations; Diabetes Mellitus; | 2012 |